 Research analysts at Oppenheimer started coverage on shares of CymaBay Therapeutics NASDAQ:CBAY in a research note issued on Monday, TipRanks reports. The firm set a buy rating and a 12.00 price target on the biopharmaceutical companys stock. Oppenheimers target price would indicate a potential upside of 145.90 from the companys previous close. Several other research ... 